title: Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice.
abstract: BACKGROUND
  Extensive evidence exists regarding the effectiveness of secondary prevention measures in patients with cardiovascular disease.
  
  
  OBJECTIVE
  We aimed to examine the management and risk perceptions of cardiovascular events in people with established cardiovascular disease.
  
  
  METHODS
  We analyzed data on 1453 patients, ≥55 year old, with a history of cardiovascular disease, from the Australian Hypertension and Absolute Risk Study.
  
  
  RESULTS
  Compared with those 533 patients with stroke/transient ischemic attack, the 743 patients with coronary artery disease were twice as likely to have been prescribed secondary prevention therapies even after adjustment for potential confounding variables (adjusted relative risks 1·85; 95% confidence interval 1·56-2·19, 42% vs. 73% for use of the combination of blood pressure-lowering, lipid-lowering and antiplatelet therapies) and to have better control of lipid and blood pressure levels. General practitioners estimated that only 27% of patients with stroke/transient ischemic attack - 38% of those with coronary artery disease and 41% of those with both conditions - were at a high risk (≥15%) of a recurrent event. Patients similarly underestimated their risk of recurrent cardiovascular events, with only 8% of stroke/transient ischemic attack, 11% of coronary and 15% of combination disease patients rating themselves at 'high' or 'very-high' risk.
  
  
  CONCLUSIONS
  This study reaffirms the large treatment gap in the uptake of secondary prevention for cardiovascular disease in primary care settings, being much greater for patients with cerebral compared with cardiac cardiovascular disease. This appears to be related to differential perceptions of cardiovascular risk across different vascular territories in both patients and doctors.
authors: The George Institute for Global Health, Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia. eheeley@george.org.au
authors: Emma
authors: E
authors: Heeley
authors: Craig
authors: C
authors: Anderson
authors: Anushka
authors: A
authors: Patel
authors: Alan
authors: A
authors: Cass
authors: David
authors: D
authors: Peiris
authors: Andrew
authors: A
authors: Weekes
authors: John
authors: J
authors: Chalmers
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000517:prevention & control*; D005260:Female; D058006:General Practice / Q000592:standards*; D054625:Healthcare Disparities; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000592:standards; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control*
chemical_list: D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors